Ajai Chari, MD, discusses the biggest challenge in treating patients with multiple myeloma.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the biggest challenge in treating patients with multiple myeloma.
The treatment landscape is very exciting, Chari says. Ten drugs have been approved over the last decade, while 4 of those were approved in 2015. However, the biggest challenge now with these patients is what happens when patients exhaust these options.
Patients who are penta-refractory are refractory to 5 of these currently approved therapies. The question is then what to do for these patients who have seemingly exhausted all options, Chari concludes.
At the 2018 ASH Annual Meeting,data from part 2 of the pivotal STORM trial
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More